SecBot SecBot
8-K ·Filed Nov 12, 2026

NSPR

InspireMD, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4d 23h ago SEC0001493152-26-051454
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

FDA approval of CGuard Prime for TCAR is a transformative regulatory milestone that enables U.S. market re-entry and a significantly larger addressable market. Monitor Q4 2026 U.S. sales commencement and the December 2026 PMA supplement submission for the CGuard Prime for CAS delivery system, which would allow a full U.S. product portfolio.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

NSPR drug pipeline →

CGuard Prime

◆ Mixed Named in this 8-K
Impact
Phase
Approved (FDA PMA)
Time to market
CGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.
Next catalyst
NDA filing · Dec 2026

What to watchThe next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.

Price Chart

Loading chart...

Executive Summary

The key event is FDA approval of CGuard Prime for TCAR procedures, which expands the U.S. addressable market by over 35,000 procedures annually and allows the company to return to the U.S. market. Revenue decline reflects the ongoing impact of the voluntary recall of the CGuard Prime for CAS delivery system, while international revenue grew 9.1%.

Key Financial Metrics

Revenue
$2.2M
est $2.0M · +12.1% · -11.1% YoY
Gross Margin
10.7%

Key Facts

  • FDA approved CGuard Prime for TCAR procedures, expanding U.S. addressable market by over 35,000 procedures annually
  • Q3 2026 total revenue $2,242,000, down 11.1% YoY from $2,523,000
  • International revenue $2,210,000, up 9.1% YoY; U.S. revenue $32,000 vs $497,000 due to recall
  • Cash and marketable securities $19,246,000 at Sept 30, 2026, down from $54,211,000 at Dec 31, 2025
  • Restructuring expenses of $1,074,000 in Q3 2026 from workforce reduction
  • CGuard Prime for CAS enhanced delivery system PMA supplement expected to be submitted in December 2026, potential re-launch in H1 2027
  • CGUARDIANS III pivotal trial for SwitchGuard neuroprotection system continuing enrollment

Financial Impact

FDA approval of CGuard Prime for TCAR expands U.S. addressable market by over 35,000 procedures annually; Q3 revenue down 11.1% YoY to $2.24M; net loss improved to $9.76M from $12.71M

revenuenet losscashoperating expenses

Segment Breakdown

SegmentRevenueGrowth
International$2.2M+9.1%
U.S.$32.0KNot reported

Risk Factors

  • Cash burn continues with only $19.2M in cash and marketable securities as of Sept 30, 2026, down from $54.2M at Dec 31, 2025
  • Voluntary recall of CGuard Prime for CAS delivery system still impacting U.S. revenue; re-launch not expected until H1 2027
  • Company has history of recurring losses and may need additional capital to fund operations and commercial launch
  • Forward-looking statements note substantial doubt about ability to continue as a going concern

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-051454
Document: form8-k.htm0001493152-26-051454
Document: 0001493152-26-051454-index-headers.html0001493152-26-051454
Document: 0001493152-26-051454-index.html0001493152-26-051454
Document: 0001493152-26-051454.txt0001493152-26-051454
8-K Data (Synthetic)0001493152-26-051454

Track record

29 reports on NSPR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
  2. Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  3. Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  4. Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  5. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  6. Nov 12, 20264d ago 8-K Bullish 7/10 Viewing No price data
  7. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  8. Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  9. Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  10. Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026